Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Gabrail Cancer Center Research | La Trobe University | Murdoch Childrens Research Institute | Medicines Development for Global Health | University of Melbourne | Swiss Tropical and Public Health Institute | University of Ottawa | The Mentor Initiative | G
Deal Size : Inapplicable
Deal Type : Inapplicable
Moxidectin Vs Ivermectin MDA For Onchocerciasis and NTDs
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Onchocerciasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2025
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Gabrail Cancer Center Research | La Trobe University | Murdoch Childrens Research Institute | Medicines Development for Global Health | University of Melbourne | Swiss Tropical and Public Health Institute | University of Ottawa | The Mentor Initiative | G
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxidectin
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Blepharitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2025
Lead Product(s) : Moxidectin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxidectin
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Moxidectin in Adults With Scabies
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scabies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Moxidectin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Onchocerciasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Moxidectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable